Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19513277 | 0.78 | GABRA1 (0.42) | PDE10AMMP2MMP9MMP8ABL1 | |
| SCHEMBL21037108 | 0.77 | AKT1 (0.40) | PDE10AMMP2MMP9MMP8ABL1 | |
| SCHEMBL29297673 | 0.76 | ABL1 (0.44) | PDE10AMMP2MMP9MMP8ABL1 | |
| SCHEMBL826949 | 0.76 | PDE10A (0.55) | PDE10AMMP2MMP9MMP8 | |
| SCHEMBL21764163 | 0.75 | MMP2 (0.37) | PDE10AMMP2MMP9MMP8ABL1 | |
| SCHEMBL20100774 | 0.74 | ABL1 (0.34) | ABL1 | |
| SCHEMBL22475741 | 0.74 | PDE10A (0.47) | PDE10AMMP2MMP9MMP8ABL1 | |
| SCHEMBL2467449 | 0.73 | ABL1 (0.47) | ABL1GABRA1GABRB2 | |
| SCHEMBL22134831 | 0.73 | CYP1A2 (0.42) | PDE10AMMP2MMP9MMP8ABL1 | |
| SCHEMBL18571624 | 0.73 | ESR2 (0.50) | PDE10AMMP2MMP9MMP8ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | PDE10A 970/4885MMP2 2139/4885MMP9 3014/4885 |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | PDE10A 970/4885MMP2 2139/4885MMP9 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.